Introduction {#Sec1}
============

In recent years, venous thromboembolism (VTE) has been increasingly recognised as a clinical problem in the paediatric population. It is associated with significant morbidity and mortality in those affected, especially children with severe underlying conditions (such as cancer) and multiple risk factors \[[@CR1]--[@CR3]\]. In the general paediatric population, the incidence of VTE is low, occurring at a rate of 0.06--0.14 per 10,000/year \[[@CR4], [@CR5]\]. However, in hospitalised children a significantly higher incidence of VTE was reported. A study conducted in the early 1990s in Canada demonstrated an incidence of VTE among paediatric patients of 5.3 per 10,000 admissions/year \[[@CR6]\]. In a US paediatric study over a period of 7 years, the incidence of VTE increased from 34 to 58 cases per 10,000 admissions/year \[[@CR1]\], with neonates and adolescents being at the greatest risk \[[@CR1], [@CR7]\]. Whether these data indicate a true increase in occurrence of VTE in the paediatric population (potentially influenced by improved survival chances of seriously ill paediatric patients owing to medical advances) or an increase in detection of previously undiagnosed VTE remains unclear. Major physiological changes in the haemostatic system throughout childhood are well documented and affect the frequency and natural history of VTE in children \[[@CR8]\]. These changes will also affect the response of children to anticoagulants \[[@CR8]\].

Guidelines from the American College of Chest Physicians recommend the use of unfractionated heparin, low-molecular-weight heparin and vitamin K antagonists for the prevention and treatment of VTE in children \[[@CR8]\]. These guidelines are based mainly on extrapolation from results of clinical trials conducted in adults because ethical and technical issues have limited the number of clinical trials in paediatric populations. Therefore, in clinical practice, there is a high level of off-label use of drugs in children: 50 % of drugs that are administered to children have not been tested in the appropriate age group \[[@CR9]--[@CR14]\]; this number increases to up to 90 % of drugs administered to preterm and term babies admitted to neonatal intensive care units \[[@CR12], [@CR13]\].

Rivaroxaban is an oral, direct Factor Xa inhibitor that has been shown to exhibit well-defined pharmacokinetic and pharmacodynamic properties, with high oral bioavailability (\>80 %) and limited food and drug interactions in healthy adults \[[@CR15]--[@CR22]\]. Rivaroxaban inhibits free and fibrin-bound Factor Xa as well as Factor Xa in the prothrombinase complex and, therefore, prevents clot formation and clot growth \[[@CR23]\]. Rivaroxaban has been widely studied in phase III clinical trials involving more than 60,000 adult patients and, based on these results, has been approved in adults for the prevention of VTE after elective hip or knee replacement surgery \[[@CR24]--[@CR27]\]; the treatment of acute, symptomatic deep vein thrombosis, treatment of acute pulmonary embolism and prevention of recurrent VTE \[[@CR28], [@CR29]\]; and the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation \[[@CR30]\]. Rivaroxaban has also successfully completed a phase III clinical trial for secondary prevention of cardiovascular events in patients after acute coronary syndrome \[[@CR31]\].

Owing to its well-defined pharmacokinetic and pharmacodynamic properties and its efficacy and safety profiles in adults, rivaroxaban warrants investigation in children. There are currently no data on the use of rivaroxaban in children; however, oral suspensions of rivaroxaban 10 and 20 mg (concentration 1 mg/mL), which have already been tested in phase I studies in healthy male adults, may be a suitable formulation for children because exact dosing is possible. It is anticipated that this oral formulation will form the basis of potential future paediatric use \[[@CR32]\].

Current regulations from the US FDA and the European Medicines Agency request development strategies for paediatric dosing recommendations for drugs that have been approved in adults. These dosing strategies aim to maintain in children (\<18 years of age) the efficacy and safety seen in adults \[[@CR33]\]. Physiologically based pharmacokinetic (PBPK) modelling strategies have been used to predict dosing regimens for paediatric clinical trials by accounting for developmental changes that affect the absorption, distribution, metabolism and excretion of drugs \[[@CR34]\]. Although pharmacodynamic modelling also plays a part, the modelling of pharmacokinetic parameters could directly inform dosing strategies in the paediatric population and, therefore, is considered the major component of paediatric modelling initiatives and, hence, is the focus of this article \[[@CR33], [@CR35]\]. Furthermore, the FDA highlights the need and value of PBPK modelling studies to improve the design of paediatric drug development studies with the ultimate aim of reducing off-label use of drugs in paediatric patients \[[@CR35], [@CR36]\].

The first objective of this study was to develop and qualify a PBPK model for rivaroxaban doses of 10 and 20 mg in adults and to scale this model to the paediatric population. The second objective was to predict the pharmacokinetic properties of rivaroxaban in children and to use this information to guide dosing in a paediatric phase I trial \[ClinicalTrials.gov identifier: NCT01145859. <http://clinicaltrials.gov/show/NCT01145859> (Accessed 19 July 2013)\]. This trial is currently ongoing and is assessing the pharmacokinetics and pharmacodynamics of rivaroxaban in paediatric patients who have completed anticoagulant treatment for VTE, but who are considered to be at risk of VTE recurrence.

Methods {#Sec2}
=======

Data Sources {#Sec3}
------------

Experimental data sets from phase I studies \[[@CR16], [@CR32], [@CR37]\] carried out in healthy adults (see Table [1](#Tab1){ref-type="table"} and the Electronic Supplementary Material: Section 1) were used to support the development and qualification of an adult PBPK model. In all studies, the rivaroxaban tablets administered were immediate-release formulations unless otherwise stated. Physiochemical data of rivaroxaban that were used in the model, including solubility, molecular weight and fraction unbound (i.e. plasma protein binding), are listed in Table [2](#Tab2){ref-type="table"}.Table 1Experimental data sets of phase I studies assessing the pharmacokinetics of rivaroxaban in healthy male adult subjectsStudyTopicMain outcomeStudy AMass balance and safety \[[@CR37]\]Rivaroxaban and its metabolites were eliminated via renal (66 %) and biliary/faecal routes (28 %)Study BAbsolute bioavailability \[[@CR32]\]Compared with a 1 mg IV dose, under fasted conditions the bioavailability of rivaroxaban 5 mg was complete and was 66 % for rivaroxaban 20 mg. Bioavailability of rivaroxaban 20 mg was 59 % relative to the 5 mg doseStudy CPharmacokinetics across a wide dose range \[[@CR16]\]Rivaroxaban had well-defined pharmacokinetic characteristics across doses of 1.25--80 mg administered as oral solution or tabletStudy DAbsorption from proximal and distal small bowel and ascending colonThe relative bioavailability of rivaroxaban depends on the site of absorption along the gastrointestinal tract and is poorest in the ascending colonStudy EFood effect on pharmacokinetics of two 5 mg tabletsCompared with fasted conditions, mean *t* ~max~, mean AUC and mean *C* ~max~ of rivaroxaban 10 mg were increased when taken with foodStudy FFood effect on pharmacokinetics of four 5 mg tablets or one 20 mg tabletThere were no pharmacokinetic differences between the two dosing regimens or between two types of meals. Mean *t* ~max~, mean AUC and mean *C* ~max~ were significantly higher after foodStudy GFood effect on pharmacokinetics of one 10 mg tablet or one 20 mg tabletBioavailability of rivaroxaban 10 mg was independent of food\
Bioavailability of rivaroxaban 20 mg was similar when taken with food and lower when taken without foodStudy HFood effect on pharmacokinetics of 10 mg and 20 mg oral solutionBioavailability of rivaroxaban 10 mg was independent of food\
Bioavailability of rivaroxaban 20 mg was similar when taken with food and lower when taken without food*AUC* area under the plasma concentration--time curve, *C* ~*max*~ maximum (peak) plasma drug concentration, *IV* intravenous, *t* ~*max*~ time to *C* ~max~Table 2Physiochemical data of rivaroxabanParameterReported valueValue used in this studyLipophilicity2.275 cLog P2.39^a^ cLog MA2.39^a^Plasma protein binding in adults Plasma *f* ~u~5.1 % \[[@CR45]\]5.1 %^b^Solubility Water solubility7 mg/L^b^ Solubility in FaSSIF/used in fasted state20 mg/L^b^20 mg/L Solubility in FeSSIF/used in fed state80 mg/L^b^80 mg/LMolecular weight435.89 g/mol^b^435.89 g/molIntestinal permeability coefficient In the small intestine4.74 × 10^−6^ cm/s In the large intestine9.48 × 10^−6^ cm/s*cLog MA* calculated Log value of the membrane affinity, *cLog P* calculated Log value of the octanol water partition coefficient, *FaSSIF* fasted state simulated intestinal fluid, *FeSSIF* fed state simulated intestinal fluid^a^Because no experimental lipophilicity value was available, the lipophilicity value had to be calculated in silico based on its chemical structure. The Bayer in-house cheminformatics tool (Pythia) was used for this purpose. Pythia requires the chemical structure as input (e.g. imported via MDL ISIS/Draw) and predicts, among other physico-chemical properties, the Log MA value using a fragment-based quantitative structure--activity relationship (QSAR) method. The tool is embedded in a Bayer in-house software platform to calculate absorption, distribution, metabolism and excretion (ADME) properties^b^Bayer HealthCare data on file

Generic Workflow for Model Development {#Sec4}
--------------------------------------

The generic workflow for the scaling of drug pharmacokinetics from adults to the paediatric population using PBPK modelling has been described previously and remained unchanged in this study (Fig. [1](#Fig1){ref-type="fig"}) \[[@CR38]\].Fig. 1Generic workflow for the PBPK-based scaling of rivaroxaban pharmacokinetics from adults to children. *ADME processes* processes that involve absorption, distribution, metabolism and excretion of a drug, *IV* intravenous, *PK* pharmacokinetic, *PBPK* physiologically based pharmacokinetic

Software Used {#Sec5}
-------------

All PBPK simulations were carried out using the commercially available software PK-Sim^®^ (Version 4.2, Bayer Technology Services, Leverkusen, Germany; <http://www.systems-biology.com>) and exported to MoBi^®^ (Version 2.3, Bayer Technology Services, Leverkusen, Germany), where a novel model for gastrointestinal transit and absorption was added, which is part of PK-Sim^®^ Version 5.0 and higher \[[@CR39], [@CR40]\].

All optimisations and batch mode simulations for MoBi models were carried out using MATLAB^®^ \[Version 7.11.0 (R2010b), The MathWorks Inc., Natick, MA, USA\] and the MoBi Toolbox for MATLAB (Version 2.3 Bayer Technology Services, Leverkusen, Germany).

Physiologically Based Pharmacokinetic (PBPK) Model for Intravenous Administration in Adults {#Sec6}
-------------------------------------------------------------------------------------------

### Lipophilicity {#Sec7}

Data from the absolute bioavailability study \[[@CR32]\] were used to modify the lipophilicity of rivaroxaban with the aim of adjusting the simulated plasma concentration--time curve based on the PBPK model to reflect the experimental data more closely, especially for the early distribution phase (Study B, Table [1](#Tab1){ref-type="table"}). The partition coefficients were estimated using the method of Rodgers and Rowland \[[@CR41]--[@CR43]\].

### Clearance Processes {#Sec8}

The rivaroxaban PBPK model contains three hepatic, first-order clearance processes and two renal clearance processes. The first hepatic process describes the clearance of rivaroxaban via cytochrome P450 (CYP) 3A4/5; the second process describes the clearance of rivaroxaban via CYP2J2; and the third hepatic process describes CYP-independent hydrolysis of rivaroxaban. Renal clearance processes include the glomerular filtration rate (GFR) and tubular secretion. Clearance percentages originally determined for oral administration according to mass balance and in vitro information were: 6 % GFR, 30 % tubular secretion, 7 % faecal unchanged, 18 % CYP3A4/5, 14 % CYP2J2, 14 % hydrolysis and 11 % unaccounted \[[@CR37], [@CR44], [@CR45]\]. Faecal excretion was disregarded and the unaccounted part was assumed to be caused by hepatic clearance processes and proportionally distributed across the three hepatic processes. Based on the unbound fraction in plasma (*f*~u~) of 5.1 % of rivaroxaban in adults, the contribution of glomerular filtration was approximately 6 mL/min (estimated from GFR × *f*~u~ = 120 mL/min × 0.051 = 6.1 mL/min) \[[@CR37], [@CR44]--[@CR46]\]. To account for the renal clearance exceeding glomerular filtration, the tubular secretion was set at 30 mL/min, resulting in a total urinary excretion of 36 mL/min.

PBPK Model for Oral Administration in Adults {#Sec9}
--------------------------------------------

After establishing the intravenous PBPK model in adults, the model was expanded to account for oral administration of rivaroxaban. To improve description of the absorption process, a recently developed compartmental model for gastrointestinal transit and absorption was implemented \[[@CR39], [@CR40]\].

For the simulations of the effect of food on pharmacokinetics of orally administered rivaroxaban in adults, the meal energy content was uniformly distributed between 593 kcal (corresponding to a high-carbohydrate "continental" breakfast \[[@CR18]\]) and 1,051 kcal (corresponding to a high-fat, high-calorie "American" breakfast \[[@CR18]\]) for the simulation of fed conditions. For both meals, solid and liquid components were estimated to be equal, i.e. 50 % each. For adults, the gastric emptying time under fed conditions was fitted to experimental data taken from the food effect study of rivaroxaban 10 mg (administered as two 5 mg tablets). According to this function, emptying from the stomach is slow during the first 2 h and then accelerates so that emptying is almost complete 5 h after drug administration \[[@CR47], [@CR48]\].

All other compound-specific parameters (including the adjusted lipophilicity parameter) and clearance were the same as in the intravenous model. The permeability coefficient for the small intestine was determined based on results from the orally administered solution (Study C, Table [1](#Tab1){ref-type="table"}), and the permeability coefficient for the large intestine was based on the absorption site study (Study D, Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"}). The dissolution behaviour of the rivaroxaban tablets was then considered via the dissolution module of PK-Sim^®^ that incorporates a Noyes--Whitney module for spherical particles into the gastrointestinal transit and absorption model \[[@CR49], [@CR50]\]. This module allows for the dynamic simulation of particle size-dependent dissolution in an environment that changes during transit through the gastrointestinal tract (e.g. pH, solubility). A more detailed description of this add-on module has been published \[[@CR50]\]. Owing to absorption being dependent on particle size, it is noteworthy that both suspension and tablet formulations contain the same micronised drug. For rivaroxaban, monodisperse particles with a median diameter of 3 μm (according to the specification of the powder), a diffusion coefficient of 4.9 × 10^−5^ cm^2^/s (fitted to experimental data \[[@CR16]\]) and a diffusion layer thickness of 20 μm (PK-Sim^®^ default) were assumed.

For model qualification, population simulations in an adult reference population were performed for 10 and 20 mg tablets first under fasted and then under fed conditions and compared with independent experimental data sets. Further, experimental data obtained in adults after administration of rivaroxaban 10 and 20 mg as oral suspension under fasting conditions and 20 mg under fed conditions were compared with simulations in an adult reference population. The quality of the adult model was judged by means of a visual predictive check (VPC), a popular tool for evaluating the performance of population pharmacokinetic/pharmacodynamic models. The VPC compares different percentiles of the experimental data with percentiles of simulated data \[[@CR51], [@CR52]\].

Rivaroxaban Doses Used in the Paediatric Simulations {#Sec10}
----------------------------------------------------

For paediatric simulations, body weight-adjusted doses of rivaroxaban were used. Doses for paediatric simulations were derived from adult doses assuming a typical body weight of 70 kg for adults. Thus, a paediatric dose of 0.143 mg/kg body weight is equivalent to a 10 mg dose in adults, and a paediatric dose of 0.286 mg/kg body weight is equivalent to a 20 mg adult dose.

Scaling of the Adult PBPK Model to Children {#Sec11}
-------------------------------------------

Using the adult PBPK model as a basis, the model was scaled to children by including anthropometric and physiological information, age-dependent clearance and age-dependent protein binding. Simulations with virtual populations of children from term neonates (assuming a birth weight of ≥2 kg) to adolescents aged 18 years were carried out. No further changes to any other input parameters (e.g. specific intestinal permeability, solubility) were made in comparison with the adult reference model.

### Anthropometric and Physiological Information {#Sec12}

The model was scaled taking into account age-dependent parameters of height and body weight and physiological parameters (blood flow, organ volumes, binding protein concentration, haematocrit, cardiac output) in children in line with previously published data \[[@CR34]\]. This information is incorporated into PK-Sim^®^ and was used as default values for the simulations in children.

### Clearance Scaling {#Sec13}

The clearances, as defined and quantified in the adult PBPK model, were scaled as published previously \[[@CR53]\]. In brief, clearance scaling was based on developmental changes regarding the major enzymes that catalyse clearance processes. When developmental changes of a clearance process were not available, enzyme activity was scaled in comparison with adult activity on a per-organ weight basis. Calculations of intrinsic clearances from plasma clearances and plasma clearances from intrinsic clearances were made using the well-stirred model \[[@CR54], [@CR55]\]. Age-dependent parameters in children (including height, body weight, blood flow, organ volumes, binding protein concentration, haematocrit and cardiac output) were used, as previously published \[[@CR53]\], and were incorporated as default values.

### Protein Binding {#Sec14}

Developmental changes in the concentration of human serum albumin in plasma were used to scale *f*~u~, as described previously \[[@CR34], [@CR56]\].

### Net Tubular Secretion {#Sec15}

Net tubular secretion of rivaroxaban was scaled, assuming that the major transport protein was P-glycoprotein (P-gp). P-gp is an adenosine triphosphate-dependent efflux pump, the ontogeny of which has not been explicitly studied in humans. Studies in mice and rats have shown inconsistent results for expression levels of P-gp in the kidney at birth (11--96 %) and the postnatal age when adult expression levels were reached (0--21 days) \[[@CR57]--[@CR59]\].

Owing to the fact that digoxin is a P-gp substrate and is primarily cleared via P-gp-mediated tubular secretion and GFR in the kidney \[[@CR59]\], digoxin renal clearance was used to estimate the ontogeny of the P-gp transporter in the kidney of humans. Adult renal clearance values for digoxin are approximately 2.5 mL/min/kg \[[@CR60], [@CR61]\], and values across the age groups of term neonates to 18 years are available in the literature \[[@CR62]--[@CR65]\]. Because renal clearance of digoxin is the sum of GFR and net tubular secretion, GFR (as calculated from Edginton et al. \[[@CR53]\]) was subtracted from total renal clearance for each data point to calculate the age-dependence of tubular secretion via P-gp.

### Absorption from the Gastrointestinal Tract {#Sec16}

For the purpose of modelling, rivaroxaban was assumed to be given to children either in the fasted state with water or in the fed state after ingestion of an intermediate- to high-calorie meal. The fasted and fed states were simulated separately and the results were then merged to represent in vivo conditions. This approach allows mimicking of the range of feeding states as expected in hospitalised children, including those randomised for the paediatric phase I trial (NCT01145859).

For simulations across the paediatric age range, assumptions and values for the gastric emptying time, specific intestinal permeability (i.e. the intestinal permeability normalised to the surface area), the pH of the gastrointestinal tract, small intestinal transit times and the intestinal surface area were used as specified in Table [3](#Tab3){ref-type="table"} (see also the Electronic Supplementary Material: Section 2 for more detailed information).Table 3Assumptions and values used for the randomisation of factors used in the study, based on data from in vitro experimentsFactorAssumptionReferencesCYP3A4Log-normal distribution with a geometric SD of 1.5 (average value of the SDs reported in the literature)\[[@CR68], [@CR71], [@CR72]\]CYP2J2Log-normal distribution with a geometric SD of 2.5 (based on the CYP2J2 mRNA distribution in postnatal liver samples)\[[@CR69]\]CYP-independent hydrolysisLog-normal distribution and a geometric SD of 1.3 (assumed empirical value)Renal clearance via GFRBy use of the equation below, three normal-distributed random variables were obtained: Hill coefficient = 15 ± 0.257, TM~50~ = 44.4 ± 1.04 weeks, and GFR~mat~ = 266 ± 60.7 min^−1^\
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### Establishment of the Virtual Paediatric Population {#Sec17}

Virtual paediatric populations were created using the population module of PK-Sim^®^ \[[@CR66], [@CR67]\]. Twenty-eight age groups were considered (ages of 0 days, 3 days, 7 days, 14 days, 1 month, 2 months, 3 months, 6 months, 9 months, 1 year, 1.5 years, and then each year from 2 to 18 years), each consisting of 250 fasted male, 250 fed male, 250 fasted female and 250 fed female children (i.e. a total of 1,000 children per age group). The population module created virtual individuals within a given age, body weight and body height or body mass index range on a stochastic approach using age-dependent distributions of demographic and physiological parameters. The details of this algorithm and the sources for the empirical physiological distributions have been published previously \[[@CR66], [@CR67]\].

The mean intrinsic clearances, as calculated for each age group, were assigned to each virtual individual first and then subsequently randomised using variation measures from literature-based in vitro experiments \[[@CR48], [@CR62], [@CR68]--[@CR86]\]. Assumptions and values used for the randomisation of CYP3A4, CYP2J2, CYP-independent hydrolysis, GFR, the kidney P-gp transporter, gastric emptying time in the fasted and the fed state, transit times of the small and the large intestine and effective surface area of intestinal sections are shown in Table [3](#Tab3){ref-type="table"}. Simulations in children for the fasted and fed states were carried out separately and subsequently pooled for the analysis to mimic the expected conditions in the paediatric clinical trial (NCT01145859).

Results {#Sec18}
=======

The previously proposed step-wise approach (Fig. [1](#Fig1){ref-type="fig"}) was used to adjust PBPK model parameters based on experimental data in adults for intravenous and oral administration of rivaroxaban. The parameters were then scaled and adjusted for paediatric populations. Based on this PBPK model, simulations in paediatric populations were performed for pharmacokinetic parameters after oral administration of doses equivalent to rivaroxaban 10 mg/70 kg (low dose equivalent to 0.143 mg/kg) body weight and rivaroxaban 20 mg/70 kg (high dose equivalent to 0.286 mg/kg) body weight.

Development and Verification of a PBPK Model for Intravenous and Oral Rivaroxaban in Adults {#Sec19}
-------------------------------------------------------------------------------------------

### Intravenous PBPK Model {#Sec20}

The plasma concentration--time profile of rivaroxaban after intravenous administration was plotted using data from the absolute bioavailability study \[[@CR32]\]. This plot was overlaid with results simulated by the PBPK reference model. A monoparametric fit identified a lipophilicity value of LogP = 2.275. Experimental data were described sufficiently accurately when simulating the pharmacokinetics of rivaroxaban after intravenous administration with this lipophilicity value (Fig. [2](#Fig2){ref-type="fig"}). This was particularly obvious in the infusion phase and the early distribution phase after discontinuation of the infusion. The adjusted lipophilicity parameter was used for all further simulations.Fig. 2Individually observed (*dots*) and simulated (*lines*) plasma concentration--time profiles for rivaroxaban after a 30-min intravenous infusion of 1 mg rivaroxaban in healthy adults depicted as a linear (*main graph*) and semi-log plot (*inset*). Simulated data are represented as geometric means (*black line*), 90 % prediction interval (*grey shaded area*) and minimum and maximum values (*dotted lines*)

### Oral PBPK Model for Solution and Tablet Formulations of Rivaroxaban {#Sec21}

After establishing the intravenous PBPK model for rivaroxaban in adults, the model was expanded to simulate absorption from the gastrointestinal tract after oral administration of rivaroxaban. The experimental plasma concentration--time data obtained after administration of oral solutions containing rivaroxaban 5 or 10 mg to fasted healthy volunteers were used to identify the specific small intestinal permeability. The specific large intestinal permeability was obtained from the data obtained in a study, in which the Enterion™ capsule was used for site-specific administration of rivaroxaban in various regions of the gastrointestinal tract \[[@CR87]\]. The intestinal permeability coefficients were adjusted to 4.74 × 10^−6^ cm/s for the small intestine and 9.48 × 10^−6^ cm/s for the large intestine. Simulations of plasma concentration--time profiles for rivaroxaban 5 and 10 mg with the adjusted permeability coefficients were sufficiently reliable compared with experimental data. A slight trend towards an overestimation of time to reach maximum (peak) plasma concentration following drug administration (*t*~max~) was observed in the simulations compared with the experimental data. After administration of the 10 mg dose, a slight underestimation of the plasma concentration measured 24 h after administration (*C*~24h~) value was evident. Experimental data for this time point were not available for the 5 mg dose.

The effect of the dissolution behaviour of rivaroxaban immediate-release tablets on the area under the plasma concentration--time curve (AUC) was considered by using an add-on dissolution module of PK-Sim^®^ for simulations of drug particle administration. The monodisperse particle dissolution parameters were optimised by comparing simulated plasma AUC with experimental data that were obtained after administration of tablets containing rivaroxaban 10 or 20 mg to fasted healthy volunteers. A diffusion coefficient of 4.9 × 10^−5^ cm^2^/s was determined by fitting the simulated curves to the experimental data. Fitting this parameter resulted in a good fit of the simulated and the experimental plasma AUC (data not shown).

As a next step, this model was qualified using independent clinical study data.

### Model Qualification {#Sec22}

To qualify the PBPK model for oral tablet administration, independent data sets obtained from several phase I studies that assessed the pharmacokinetics of rivaroxaban 10 and 20 mg administered as tablets in healthy adults under fasted and fed conditions were compared with the corresponding simulation (Fig. [3](#Fig3){ref-type="fig"}). These results showed that, overall, the adult PBPK model is well suited to describe the pharmacokinetics of rivaroxaban after oral tablet administration under fasted and fed conditions. The majority of individual data points observed experimentally were within the 90 % prediction interval (Fig. [3](#Fig3){ref-type="fig"}). The model, however, tended to underestimate maximum (peak) plasma drug concentration (*C*~max~) slightly and to overestimate *t*~max~ for some individuals after receiving tablets under fasted conditions. The *C*~24h~ values were uniformly distributed around the simulated geometric mean and were all confined within the 90 % prediction interval of the virtual population. In the fed state, most of the observed data points were located between the simulated geometric mean and the predicted 90 % percentile of the population. There was a slight mismatch between simulated and observed plasma concentrations after intake of rivaroxaban 10 or 20 mg with food, indicating that the distinct lag time observed in some individuals after administration of the immediate-release tablet under fed conditions was not adequately represented in the model.Fig. 3Individually observed (*dots*) and simulated (*lines*) plasma concentration--time profiles for rivaroxaban after oral administration of an immediate-release tablet to healthy adults depicted as a linear (*main graph*) and semi-log plot (*inset*). Simulated data are represented as geometric means (*black line*), 90 % prediction interval (*grey shaded area*) and minimum and maximum values (*dotted lines*). The graphs show concentration--time profiles of 10 mg (**a**, **c**) and 20 mg (**b**, **d**) rivaroxaban, under fasting (**a**, **b**) and fed (**c**, **d**) conditions

Model predictions were also compared with data obtained from a phase I study that assessed the bioavailability of the suspension formulation intended for future clinical use in paediatric studies \[[@CR32]\]. The plasma concentration--time profiles for rivaroxaban 10 and 20 mg suspension formulations administered under fasted conditions and 20 mg suspension under fed conditions were well described by the model as assessed by VPC. Most experimental data points were within the 90 % prediction interval, leading to a good agreement between simulated and experimental data. A slight trend towards underestimating the inter-individual variability was evident. The considerable delay in the absorption of tablet formulations when taken with food was not observed for the absorption of the suspension. In summary, these results demonstrate that the pharmacokinetics of rivaroxaban after oral administration of a tablet or suspension under fasted and fed conditions are well described by the PBPK model that was adjusted for gastrointestinal transit and absorption.

Paediatric PBPK Model of Rivaroxaban {#Sec23}
------------------------------------

For simulations in the paediatric population, doses of rivaroxaban (oral suspension formulation) were weight-adjusted to yield a low dose and a high dose equivalent to rivaroxaban 10 mg/70 kg body weight (0.143 mg/kg body weight) and rivaroxaban 20 mg/70 kg body weight (0.286 mg/kg body weight) in adults. Apart from anthropometric differences, there were no differences in simulations for male and female children and, therefore, sex-specific simulations were pooled (Fig. [4](#Fig4){ref-type="fig"}a--f).Fig. 4Gender-pooled paediatric simulations for maximum (peak) plasma drug concentration (*C* ~max~) (**a**, **b**), area under the plasma concentration--time curve (AUC) (**c**, **d**) and concentration in plasma after 24 h (*C* ~24h~) (**e**, **f**) versus body weight for two different doses of rivaroxaban: 0.143 mg/kg body weight (**a**, **c**, **e**) and 0.286 mg/kg body weight (**b**, **d**, **f**), simulated as oral suspension formulation compared with the adult reference population. Simulated data of the paediatric population are represented as geometric means (*blue line*) and 90 % prediction interval (*grey shaded area*). Simulated data of the adult reference population are represented as geometric means (*thick red line*) and 90 % confidence interval (*red shaded area* in the background of the graph). Expected body weight ranges for infants, preschool children, children and adolescents are indicated

Simulations with the paediatric PBPK model for the low dose and the high dose (corrected for body weight) resulted in similar graphs for *C*~max~, AUC and *C*~24h~ values versus body weight (Fig. [4](#Fig4){ref-type="fig"}a--f). As expected, the values for these pharmacokinetic parameters with the high dose were consistently higher than the low dose. For both doses, simulated *C*~max~, AUC and *C*~24h~ values for infants and children up to 40 kg body weight were much lower than the 90 % confidence interval (CI) of the adult reference population (Fig. [4](#Fig4){ref-type="fig"}a--f): the effect was most pronounced for *C*~24h~ values. In children with higher body weight and in adults of \>70 kg body weight, the simulated 90 % prediction interval values of AUC and *C*~24h~ were much higher than the 90 % CI of the adult reference population, but this is not the case for the simulated *C*~max~ values (Fig. [4](#Fig4){ref-type="fig"}a, b).

The predicted geometric means of *C*~max~, AUC and *C*~24h~ values for all simulated age groups and both doses were located within the 90 % CI of the adult reference population. However, a trend towards lower mean plasma exposures and trough concentrations of rivaroxaban can be observed in preschool children and infants (body weight below 40 kg).

Discussion {#Sec24}
==========

An established workflow for PBPK-based scaling from adults to children was used for the prediction of rivaroxaban pharmacokinetics in children. Based on extensive clinical data, the adult reference model could successfully be parameterised. Parameters that were adjusted based on the experimental data sets obtained in adults include the lipophilicity and the diffusion coefficient for the monodisperse particle dissolution. It is noteworthy that the intravenous administration in the absolute bioavailability study was purely of an experimental nature and that rivaroxaban is only to be used as an oral formulation in clinical practice. In addition, phase I studies in healthy male adults demonstrated that there was no difference between suspension and tablet formulations of rivaroxaban with respect to pharmacokinetic parameters and bioavailability \[[@CR32]\]; this is in part because both formulations contain the same micronised drug. The model accounts for different permeability parameters in the small and large intestine in a novel model for gastrointestinal transit and absorption. An important aspect of this PBPK model is that absorption from the large intestine is considered, because, unlike many other oral substances, the large intestine contributes significantly to the overall absorption of rivaroxaban. After successful development of the adult reference model, the PBPK model was scaled for children based on anatomical, physiological and developmental information.

The body weight-related dosing regimen led to a large overlap of the simulated plasma pharmacokinetic parameters (*C*~max~, *C*~24h~ and AUC) for all age ranges with the values obtained in the corresponding adult reference simulation. Importantly, *C*~24h~ is the lowest concentration in a once-daily dosing regimen, and thus is an important parameter to assess efficacy and an important driver in the decision for paediatric dosing. Paediatric dosing should achieve pharmacokinetic profiles within the 90 % CI of the adult reference model, and simulated *C*~24h~ values should not drop below the threshold of the 90 % CI. Therefore, especially in infants and preschool children (body weight below 40 kg), the simulated dose with respect to body weight is too low as indicated by *C*~24h~ values close or below the 90 % CI threshold. This result indicates that dosing for these children would need to be increased to achieve pharmacokinetics similar to those in the adult population. For older children, simulated plasma pharmacokinetic parameters (*C*~max~, *C*~24h~ and AUC) overlapped with the values obtained in the corresponding adult reference simulation, indicating that body weight-related exposure was similar between these children and adults. In children with higher body weight and in adults of \>70 kg body weight, the simulated 90 % prediction interval values of AUC and *C*~24h~ were much higher than the 90 % CI of the adult reference population owing to the simulations for children being based on weight-dependent dosing (i.e. rivaroxaban mg/kg body weight). This resulted in an overestimation of dosing for heavier body weights because the adult reference population takes into account those patients with body weight ≥70 kg who receive fixed 10 or 20 mg doses of rivaroxaban (not weight adjusted).

In adults, rivaroxaban 10 mg can be taken with or without food, but the 20 mg dose should be taken with food to achieve high oral bioavailability \[[@CR32]\]. The assumption of children being 50 % fed and 50 % fasted reflected the proposed study design for the ongoing phase I study (NCT01145859) and is in line with guidelines for the design of paediatric studies \[[@CR88]\]. This is the first study to investigate rivaroxaban in paediatric patients, and is designed to explore the pharmacokinetic and pharmacodynamic profile of single doses of rivaroxaban in patients (aged between 6 months and 18 years) at the end of VTE treatment.

One potential limitation of the developed paediatric model is that it is based on the assumption of a normal, healthy development (especially with respect to organ development of the liver and kidney). Therefore, the model may be used to inform dosing in healthy children who require a major surgery and hence will be at risk of VTE. In adults, in the first 2 postoperative days caution is recommended because the pharmacokinetics of rivaroxaban are more variable than at steady state \[[@CR89]\]; this may also be the case in children. The proposed model does not account for the effects of comorbidities, such as cystic fibrosis or cancer, or other conditions that could potentially influence rivaroxaban exposure. Developmental delays that will affect the pharmacokinetics of rivaroxaban in children have to be taken into account when considering body weight-related dosing.

By definition, traditional compartmental modelling approaches have limited predictive capability because they will not account for all of the physiological, anatomical and/or biochemical changes associated with development, nor for how the absorption, distribution, metabolism and excretion of the drug may be affected by these changes \[[@CR33]\]. As described in this article, the paediatric PBPK model for rivaroxaban takes into account various developmental changes including changes in gastrointestinal physiology and motility (see Table [3](#Tab3){ref-type="table"} and Methods section). This PBPK scaling approach allowed an exploratory analysis of the pharmacokinetics of rivaroxaban in children to inform the dosing regimen for the clinical study in paediatric patients. It will also be interesting to investigate the pharmacodynamics of rivaroxaban in children. In adults, there is a good correlation between the pharmacokinetics and pharmacodynamics of rivaroxaban, with parameters such as Factor Xa inhibition and prolongation of prothrombin time being closely correlated with plasma concentrations of rivaroxaban \[[@CR15], [@CR16], [@CR90], [@CR91]\]. Such correlations are expected also to apply to the paediatric population.

Conclusions {#Sec25}
===========

The pharmacokinetic properties of rivaroxaban in children have been simulated for two body weight-related dosing regimens equivalent to 10 and 20 mg once daily in adults using a newly developed paediatric PBPK model. Simulations for AUC, *C*~max~ and *C*~24h~ with respect to body weight as an indicator for age showed a large overlap with values obtained for the corresponding dose in the adult reference simulation. However, pharmacokinetic values in infants and preschool children were lower than the 90 % CI threshold of the adult reference model, indicating that doses in these children may need to be increased to achieve the desired pharmacokinetic profile. This PBPK scaling approach allowed an exploratory analysis of the pharmacokinetics of rivaroxaban in children to inform the dosing regimen for the clinical study in paediatric patients.
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